Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Nature

Volumn 486, Issue 7404, 2012, Pages 532-536

  Misale, Sandra ^a,b   Yaeger, Rona ^c   Hobor, Sebastijan ^a   Scala, Elisa ^a,b   Janakiraman, Manickam ^c   Liska, David ^c   Valtorta, Emanuele ^d   Schiavo, Roberta ^d   Buscarino, Michela ^a,b   Siravegna, Giulia ^a   Bencardino, Katia ^d   Cercek, Andrea ^c   Chen, Chin Tung ^c   Veronese, Silvio ^d   Zanon, Carlo ^a   Sartore Bianchi, Andrea ^d   Gambacorta, Marcello ^d   Gallicchio, Margherita ^b   Vakiani, Efsevia ^c   Boscaro, Valentina ^b   Medico, Enzo ^a,b   Weiser, Martin ^c   Siena, Salvatore ^d   Di Nicolantonio, Federica ^a,e   Solit, David ^c   Bardelli, Alberto ^a,b,e   more..

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PANITUMUMAB; RECOMBINANT VASCULOTROPIN;

ANTIBODY; CANCER; DRUG RESISTANCE; INHIBITION; RADIOGRAPHY;

ALLELE; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; COLORECTAL CANCER; GENE EXPRESSION; GENE MUTATION; HUMAN; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION;

ALLELES; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENES, RAS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84862999938     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11156     Document Type: Article

References (21)

1. Ciardiello, F. & Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174 (2008).
2. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
3. Wheeler, D. L. et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27, 3944-3956 (2008).
4. Benavente, S. et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin. Cancer Res. 15, 1585-1592 (2009).
5. Li, C., Iida, M., Dunn, E. F., Ghia, A. J. & Wheeler, D. L. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28, 3801-3813 (2009).
6. Hatakeyama, H. et al.Regulation ofheparin-bindingEGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS ONE 5, e12702 (2010).
7. Yonesaka, K. et al. Activation of ERBB2 signaling causes resistance to the EGFRdirected therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86 (2011).
8. Montagut, C. et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nature Med. 18, 221-223 (2012).
9. Moroni, M. et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6, 279-286 (2005).
10. De Roock, W. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortiumanalysis. Lancet Oncol. 11, 753-762 (2010).
11. Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nature Med. 14, 985-990 (2008).
12. Di Nicolantonio, F. et al. Replacement of normal withmutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc. Natl Acad. Sci. USA 105, 20864-20869 (2008).
13. Bardelli, A. & Siena, S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28, 1254-1261 (2010).
14. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
15. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
16. Janne, P. A. Challenges of detecting EGFR T790M in gefitinib/erlotinib- resistant tumours. Lung Cancer 60 (suppl. 2), S3-S9 (2008).
17. Engelman, J. A. et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116, 2695-2706 (2006).
18. Arcila, M. E. et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin. Cancer Res. 17, 1169-1180 (2011).
19. Molinari, F. et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin. Cancer Res. 17, 4901-4914 (2011).
20. Whitehead, R. H., Macrae, F. A., St John, D. J. & Ma, J. A colon cancer cell line (LIM1215) derived froma patient with inherited nonpolyposis colorectal cancer. J. Natl. Cancer Inst. 74, 759-765 (1985).
21. Smith, G. et al. Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours-implications for personalised cancer medicine. Br. J. Cancer 102, 693-703 (2010).